A neglected epidemic: Fungal infections in HIV/AIDS

Trends in Microbiology

Volumn 22, Issue 3, 2014, Pages 120-127

  Armstrong James, Darius ^a   Meintjes, Graeme ^b   Brown, Gordon D ^b,c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

AIDS; Fungal infection; HIV; Immunity; Mycoses

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; RECOMBINANT GAMMA INTERFERON; ANTIRETROVIRUS AGENT; CLINDAMYCIN; COTRIMOXAZOLE; FUNGUS VACCINE; NEW DRUG; PRIMAQUINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; BONE MARROW CELL; CELL FUNCTION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DIAGNOSTIC TEST; DIMORPHIC FUNGAL INFECTION; DISEASE ASSOCIATION; DRUG EFFICACY; EPIDEMIC; ESOPHAGUS CANDIDIASIS; FUNGUS IMMUNITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNOTHERAPY; MUCOCUTANEOUS CANDIDIASIS; MYCOSIS; NEGLECTED DISEASE; NONHUMAN; OROPHARYNX CANDIDIASIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; DISEASE SURVEILLANCE; FUNGAL STRAIN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNIZATION; IMMUNOPATHOLOGY; INCIDENCE; MORTALITY; PANDEMIC; PREVALENCE; RAPID TEST;

AIDS; FUNGAL INFECTION; HIV; IMMUNITY; MYCOSES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; HUMANS; MYCOSES; PREVALENCE; SURVIVAL ANALYSIS;

EID: 84896707227     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.01.001     Document Type: Review

References (74)

1. Fisher M.C., et al. Emerging fungal threats to animal, plant and ecosystem health. Nature 2012, 484:186-194.
2. Brown G.D., et al. Hidden killers: human fungal infections. Sci. Transl. Med. 2012, 4:165rv13.
3. Brown G.D., et al. AIDS-related mycoses: the way forward. Trends Microbiol. 2014, 22:107-109.
4. Jaffe H.W., et al. Acquired immune deficiency syndrome in the United States: the first 1,000 cases. J. Infect. Dis. 1983, 148:339-345.
5. Park B.J., et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-530.
6. + memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. J. Infect. Dis. 2013, 207:1817-1828.
7. Day J.N., et al. Combination antifungal therapy for cryptococcal meningitis. N. Engl. J. Med. 2013, 368:1291-1302.
8. Jackson A.T., et al. A phase II randomized controlled trial adding oral flucytosine to high-dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis. AIDS 2012, 26:1363-1370.
9. Lowe D.M., et al. Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression. PLoS ONE 2013, 8:e69969.
10. Maini R., et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg. Infect. Dis. 2013, 19:386-392.
11. Djawe K., et al. Environmental risk factors for Pneumocystis pneumonia hospitalizations in HIV patients. Clin. Infect. Dis. 2013, 56:74-81.
12. Pliquett R.U., et al. A Pneumocystis jirovecii pneumonia outbreak in a single kidney-transplant center: role of cytomegalovirus co-infection. Eur. J. Clin. Microbiol. Infect. Dis. 2012, 31:2429-2437.
13. Helweg-Larsen J., et al. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J. Antimicrob. Chemother. 2009, 64:1282-1290.
14. Costiniuk C.T., et al. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200cells/μL and virologic suppression: a systematic review. PLoS ONE 2011, 6:e28570.
15. Sage E.K., et al. Prognostic value of C-reactive protein in HIV-infected patients with Pneumocystis jirovecii pneumonia. Int. J. STD AIDS 2010, 21:288-292.
16. Armstrong-James D., et al. A prognostic scoring tool for identification of patients at high and low risk of death from HIV-associated Pneumocystis jirovecii pneumonia. Int. J. STD AIDS 2011, 22:628-634.
17. Patel P.K., et al. The changing epidemiology of oropharyngeal candidiasis in patients with HIV/AIDS in the era of antiretroviral therapy. AIDS Res. Treat. 2012, 2012:262471.
18. Kwamin F., et al. Distribution of Candida species among HIV-positive patients with oropharyngeal candidiasis in Accra, Ghana. J. Infect. Dev. Ctries. 2013, 7:41-45.
19. Brilhante R.S., et al. Histoplasmosis in HIV-positive patients in Ceara, Brazil: clinical-laboratory aspects and in vitro antifungal susceptibility of Histoplasma capsulatum isolates. Trans. R. Soc. Trop. Med. Hyg. 2012, 106:484-488.
20. Wheat L.J., et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob. Agents Chemother. 2001, 45:2354-2357.
21. Hanf M., et al. HIV-associated histoplasmosis in French Guiana: recent infection or reactivation?. AIDS 2010, 24:1777-1778.
22. Lofgren S.M., et al. Histoplasmosis among hospitalized febrile patients in northern Tanzania. Trans. R. Soc. Trop. Med. Hyg. 2012, 106:504-507.
23. Kenyon C., et al. A dimorphic fungus causing disseminated infection in South Africa. N. Engl. J. Med. 2013, 369:1416-1424.
24. Ustianowski A.P., et al. Penicillium marneffei infection in HIV. Curr. Opin. Infect. Dis. 2008, 21:31-36.
25. Larsson M., et al. Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam. AIDS Res. Ther. 2012, 9:24.
26. Holding K.J., et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin. Infect. Dis. 2000, 31:1253-1257.
27. + T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol. Rev. 2013, 254:54-64.
28. Cassone A., Cauda R. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS 2012, 26:1457-1472.
29. + T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax 2011, 66:375-382.
30. Rallon N., et al. Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. J. Antimicrob. Chemother. 2013, 68:2616-2625.
31. Myers R.C., et al. STAT4-dependent and -independent Th2 responses correlate with protective immunity against lung infection with Pneumocystis murina. J. Immunol. 2013, 190:6287-6294.
32. Robertson E.J., et al. Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J. Infect. Dis. 2013, 209:74-82.
33. Pensieroso S., et al. B-cell subset alterations and correlated factors in HIV-1 infection. AIDS 2013, 27:1209-1217.
34. Cubas R.A., et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 2013, 19:494-499.
35. Rethi B., et al. Concerted effect of lymphopenia, viraemia and T-cell activation on Fas expression of peripheral B cells in HIV-1-infected patients. AIDS 2013, 27:155-162.
36. Casadevall A., Pirofski L.A. Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma. Infect. Immun. 2007, 75:5074-5078.
37. Cordero R.J., et al. Antibody binding to Cryptococcus neoformans impairs budding by altering capsular mechanical properties. J. Immunol. 2013, 190:317-323.
38. Rohatgi S., Pirofski L.A. Molecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection. J. Immunol. 2012, 189:5820-5830.
39. Subramaniam K.S., et al. The absence of serum IgM enhances the susceptibility of mice to pulmonary challenge with Cryptococcus neoformans. J. Immunol. 2010, 184:5755-5767.
40. Gingo M.R., et al. Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia. J. Acquir. Immune Defic. Syndr. 2011, 57:190-196.
41. Rapaka R.R., et al. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J. Exp. Med. 2010, 207:2907-2919.
42. Tan J., Sattentau Q.J. The HIV-1-containing macrophage compartment: a perfect cellular niche?. Trends Microbiol. 2013, 21:405-412.
43. Collini P., et al. Monocyte and macrophage dysfunction as a cause of HIV-1 induced dysfunction of innate immunity. Curr. Mol. Med. 2010, 10:727-740.
44. Zhu D.M., et al. HIV infection enhances TRAIL-induced cell death in macrophage by down-regulating decoy receptor expression and generation of reactive oxygen species. PLoS ONE 2011, 6:e18291.
45. Victoria S., et al. Activation of Toll-like receptor 2 increases macrophage resistance to HIV-1 infection. Immunobiology 2013, 218:1529-1536.
46. Vachot L., et al. Candida albicans-induced DC activation partially restricts HIV amplification in DCs and increases DC to T-cell spread of HIV. J. Acquir. Immune Defic. Syndr. 2008, 48:398-407.
47. Miller E., Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol. Rev. 2013, 254:170-189.
48. + T cells. PLoS ONE 2011, 6:e27609.
49. An P., et al. Role of exonic variation in chemokine receptor genes on AIDS: CCRL2 F167Y association with pneumocystis pneumonia. PLoS Genet. 2011, 7:e1002328.
50. Loyse A., et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect. Dis. 2013, 13:629-637.
51. Armstrong-James D., et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax 2011, 66:537-538.
52. Cushion M.T., et al. Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE 2010, 5:e8524.
53. Lobo M.L., et al. Therapeutic potential of caspofungin combined with trimethoprim-sulfamethoxazole for pneumocystis pneumonia: a pilot study in mice. PLoS ONE 2013, 8:e70619.
54. Jarvis J.N., et al. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS ONE 2013, 8:e69288.
55. Jarvis J.N., et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 2011, 53:1019-1023.
56. Karageorgopoulos D.E., et al. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin. Microbiol. Infect. 2013, 19:39-49.
57. To K.K., et al. Use of nasopharyngeal aspirate for diagnosis of pneumocystis pneumonia. J. Clin. Microbiol. 2013, 51:1570-1574.
58. Zhang X., et al. Evaluation of commercially available reagents for the diagnosis of histoplasmosis infection in immunocompromised patients. J. Clin. Microbiol. 2013, 51:4095-4101.
59. Wang Y.F., et al. Immunoassays based on Penicillium marneffei Mp1p derived from Pichia pastoris expression system for diagnosis of penicilliosis. PLoS ONE 2011, 6:e28796.
60. Pyrgos V., et al. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS ONE 2013, 8:e56269.
61. Bamba S., et al. Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy. AIDS 2012, 26:1039-1041.
62. Boulware D.R., et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 2010, 7:e1000384.
63. Chang C.C., et al. Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. J. Infect. Dis. 2013, 208:1604-1612.
64. Bisson G.P., et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin. Infect. Dis. 2013, 56:1165-1173.
65. Njei B., et al. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis. Cochrane Database Syst. Rev. 2013, 2:CD009012.
66. Ricks D.M., et al. Dectin immunoadhesins and pneumocystis pneumonia. Infect. Immun. 2013, 81:3451-3462.
67. Wang J., et al. Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia. PLoS Pathog. 2010, 6:e1001058.
68. Bhagwat S.P., et al. Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of pneumocystis pneumonia. J. Immunol. 2010, 184:497-502.
69. Ho A., et al. Penicillium marneffei infection presenting as an immune reconstitution inflammatory syndrome in an HIV patient. Int. J. STD AIDS 2010, 21:780-782.
70. De Lavaissiere M., et al. Reconstitution inflammatory syndrome related to histoplasmosis, with a hemophagocytic syndrome in HIV infection. J. Infect. 2009, 58:245-247.
71. Jarvis J.N., et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012, 26:1105-1113.
72. Larsen R.A., et al. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 2005, 49:952-958.
73. Wozniak K.L., et al. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis. PLoS ONE 2009, 4:e6854.
74. Zhang Z., et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS 2013, 27:1283-1293.